Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 10/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12600702 | 0.91 | CHRM2 (0.48) | CHRM2CHRM3SMN1; SMN2HTR1AADRA1B | |
| SCHEMBL12600977 | 0.83 | HTR1A (0.48) | HTR1AADRA1BADRA1ADRD2ADRA1D | |
| SCHEMBL18463363 | 0.79 | HTR1A (0.52) | HTR1AADRA1BADRA1ADRD2ADRA1D | |
| SCHEMBL8283745 | 0.78 | HTR1A (0.43) | SMN1; SMN2HTR1AADRA1BADRA1ADRD2 | |
| SCHEMBL8282902 | 0.78 | HTR1A (0.43) | SMN1; SMN2HTR1AADRA1BADRA1ADRD2 | |
| SCHEMBL6580269 | 0.75 | HTR1A (0.48) | HTR1AADRA1BADRA1ADRD2ADRA1D | |
| SCHEMBL9386416 | 0.75 | HTR1A (0.48) | HTR1AADRA1BADRA1ADRD2ADRA1D | |
| SCHEMBL8943556 | 0.75 | HTR1A (0.48) | HTR1AADRA1BADRA1ADRD2ADRA1D | |
| SCHEMBL6751068 | 0.75 | HTR1A (0.49) | HTR1AADRA1BADRA1ADRD2ADRA1D | |
| SCHEMBL8088243 | 0.75 | CHRM2 (0.46) | CHRM2CHRM3HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044216-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | Seqirus UK Limited (GB) | 2017-02-16 | — | — | US | disclosed |
| EP-1730142-B1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CHRM2 999/4885CHRM3 651/4885SMN1; SMN2 877/4885 |
| US-20170044216-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | MRPL21, CHLSN, MAX | CHRM2 4669/4885CHRM3 4338/4885SMN1; SMN2 3641/4885 |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | CHRM2 4860/4885CHRM3 4753/4885SMN1; SMN2 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.